Preventing the cardiotoxicity of anthracyclines by dexrazoxane
- 23 October 1999
- Vol. 319 (7217), 1085-1086
- https://doi.org/10.1136/bmj.319.7217.1085
Abstract
Anthracyclines such as doxorubicin are among the most widely used anticancer drugs and are often given to children as part of curative regimens Yet long term cardiac damage is a major adverse effect that limits the effectiveness of these drugs, particularly in children. The introduction of dexrazoxane to limit the cardiotoxicity of anthracyclines is a real advance in the treatment of some forms of cancer. Cardiotoxicity induced by anthracyclines primarily affects the myocardium and is dose related, cumulative, and irreversible. Each dose of the anthracycline doxorubicin produces an increment of myocardial damage The normal heart can compensate for this until a lifetime dose of some 450 mg/m2 has been reached, after which the compensatory cardiac mechanisms begin to fail. In childhood malignancies, which may be cured if sufficient anthracyclines can be given, cardiotoxicity is more erratic and severe than in adults.1 Each dose may unpredictably cause severe toxicity, or subclinical cardiotoxicity may become overt only in adolescence or early adulthood.2 A way of preventing cardiotoxicity in children taking anthracyclines will therefore prevent not …Keywords
This publication has 11 references indexed in Scilit:
- Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.Journal of Clinical Oncology, 1998
- Overview and historical development of dexrazoxane.1998
- Chemical, Biological and Clinical Aspects of Dexrazoxane and Other BisdioxopiperazinesCurrent Medicinal Chemistry, 1998
- Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.Journal of Clinical Oncology, 1997
- Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.Journal of Clinical Oncology, 1997
- Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.Heart, 1993
- ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.Journal of Clinical Oncology, 1992
- Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in ChildhoodNew England Journal of Medicine, 1991
- Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529)Pharmacology & Therapeutics, 1990
- Prevention of the Cardiotoxic Effects of Adriamycin and Daunomycin in the Isolated Dog HeartExperimental Biology and Medicine, 1972